InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR)
("InterCure" or the “Company”) announced today the grand opening of
its flagship Cookies pharmacy in Be'er Sheva, the largest city in
Israel's southern region, known as the capital of the Negev.
The pharmacy is located in the center of Be'er
Sheva in front of City Hall, in a unique building that covers an
area of over 1,000 square meters and is painted entirely in the
globally recognized Cookies baby blue. To the Company’s knowledge,
this is the largest medical cannabis dedicated pharmacy in the
world.
The pharmacy premises and staff are uniquely
adapted to serve Israel's rapidly growing medical cannabis patient
community, which includes, among other things, the largest pharmacy
safe room in Israel, with a capacity to store over a ton of medical
cannabis products.
InterCure is marking the occasion with grand
opening festivities throughout the day, which include live music,
food trucks, deals and special offers for all patients living in
Be'er Sheva and the surrounding towns. Additionally, for the first
time, patients in the south will have access to the highly demanded
Cookies GMP products such as: Cake Mix, Melonatta, Fly and Ooh La
La, cultivated at IntreCure's southern facility.
"We are happy to bring our unmatched quality
experience to patients in southern Israel," said InterCure’s Chief
Executive Officer, Alexander Rabinovitch. "Be'er Sheva is the ideal
location for the launch of our flagship Cookies pharmacy, meeting
the needs of local patients suffering from a lack in professional
service and high-quality products. We are proud to invest in the
capital of the south and to open the largest medical cannabis
dedicated pharmacy with the widest selection of high-quality
branded products, meeting the needs of patients and laying the
infrastructure for the future adult use market."
“We are incredibly excited to open Cookies in
Be'er Sheva with InterCure. InterCure’s best-in-class production
capabilities continue to deliver the highest quality medicine to
patients in Israel, and we are thrilled to continue to expand our
global footprint with them," said Parker Berling, President of
Cookies.
About InterCure
InterCure (NASDAQ: INCR) (TSX: INCR.U) (TASE:
INCR) is the leading, profitable, and fastest growing cannabis
company outside of North America. Canndoc, a wholly owned
subsidiary of InterCure, is Israel’s largest licensed cannabis
producer and one of the first to offer Good Manufacturing Practices
(GMP) certified and pharmaceutical-grade medical cannabis products.
Cannolam LTD, a subsidiary of the Company, is a pioneer in medical
grade cannabis treatment and the retail arm of InterCure, currently
operating 23 pharmacies in Israel. InterCure leverages its market
leading distribution network, best in class international
partnerships and a high-margin vertically integrated "seed-to-sale"
model to lead the fastest growing cannabis global market outside of
North America.
For more information, visit:
http://www.intercure.co.
About Cookies
Cookies, founded in 2010 by Billboard-charting
rapper and entrepreneur Berner and Bay Area breeder and cultivator
Jai, is the most globally recognized cannabis company in the world.
Cookies values the power of the plant and focuses on creating
game-changing genetics. The company offers a collection of over 70
proprietary cannabis cultivarsstrains and more than 2,000 products.
Cookies also actively works to enrich communities
disproportionately impacted by the War on Drugs through advocacy
and social equity initiatives. Headquartered in San Francisco, the
company opened its first retail store in 2018 in Los Angeles and
has since expanded to over 450 retail locations in 17 markets
across 54 countries. Cookies was named one of America’s Hottest
Brands of 2021 by AdAge; the first cannabis brand to ever receive
this accolade. Learn more at www.cookies.co
Forward-Looking Statements
This press release may contain forward-looking
statements. Forward-looking statements may include, but are not
limited to, statements relating to InterCure’s objectives, plans
and strategies, as well as statements, other than historical facts,
that address activities, events or developments that InterCure
intends, expects, projects, believes or anticipates will or may
occur in the future, including with respect to the success of the
Cookies store launched in Be'er Sheva and its future expansion.
These statements are often characterized by terminology such as
“believes”, “hopes”, “may”, “anticipates”, “should”, “intends”,
“plans”, “will”, “expects”, “estimates”, “projects”, “positioned”,
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception
of historical trends, current conditions, expected future
developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements. Many factors could cause InterCure’s actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements, including, but
not limited to, the following: the Company’s future revenue growth
and profitability, the expected operations, financial results
business strategy, competitive strengths, expansion strategy to
major markets worldwide, the legalization of CBD in Israel and its
impacts on the Company, the impact of the COVID-19 pandemic and the
war in Ukraine. Forward-looking information is based on a number of
assumptions and is subject to a number of risks and uncertainties,
many of which are beyond InterCure’s control, which could cause
actual results and events to differ materially from those that are
disclosed in or implied by such forward-looking information. Such
risks and uncertainties include, but are not limited to: changes in
general economic, business and political conditions, changes in
applicable laws, the Israeli, U.S. and Canadian regulatory
landscapes and enforcement related to cannabis, changes in public
opinion and perception of the cannabis industry, reliance on the
expertise and judgment of senior management, as well as the factors
discussed under the heading “Risk Factors” in the Company Annual
Information Form dated April 5, 2022 which is available on SEDAR at
www.sedar.com, and under the heading “Risk Factors” and “Cautionary
Note Regarding Forward-Looking Statements” in the registration
statement on Form 20-F, filed with the Securities Exchange
Commission on April 28, 2022. InterCure undertakes no obligation to
update such forward-looking information, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable law.
Contact:
InterCure Ltd.Amos Cohen, Chief Financial
Officeramos@intercure.co
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/c0621b03-ce66-4a12-96b4-20ed2b562fcb
Intercure (TSX:INCR.U)
Historical Stock Chart
From May 2024 to Jul 2024
Intercure (TSX:INCR.U)
Historical Stock Chart
From Jul 2023 to Jul 2024